| HOME >> MEDICINE >> TECHNOLOGY |
Table 34: Retinal Vein Occlusion Therapeutics, Global, Key Companies Participating Clinical Trials, 2012 59
Table 35: Regeneron - Ophthalmology Pipeline Products, 2012 63
Table 36: Novartis - Ophthalmology Pipeline Products, 2012 65
Table 37: Roche - Ophthalmology Pipeline Products, 2012 67
Table 38: Allergan, Inc. - Ophthalmology Pipeline Products, 2012 68
Table 39: Retinal Vein Occlusion Therapeutics, Global, Deals, 2009-2011 69
List of Figures
1.2 List of FiguresFigure 1: Branch Retinal Vein Occlusion 7Figure 2: Central Vein Retinal Occlusion 8Figure 3: Ischemic Central Retinal Vein Occlusion 8Figure 4: Nonischemic Central Retinal Vein Occlusion 9Figure 5: KOL Insights, Future Trends in the Prevalence for the RVO in the US and Europe 10Figure 6: Pharmacoeconomic Burden of Retinal Vein Occlusion 12Figure 7: Branch Retinal Vein Occlusion in the Superotemporal Quadrant of the Right Eye 15Figure 8: Nonperfused Central Retinal Vein Occlusion in the Left Eye 15Figure 9: Assessment of Cardiovascular Risk in Patients with Retinal Vein Occlusion 16Figure 10: KOL Insights, Treatment and Management Patterns 16Figure 11: KOL Insights, Usage Patterns for the Pharmacological Treatment Options 19Figure 12: Retinal Vein Occlusion Therapeutics Market, Global, Revenue ($m), 2006- 2011 23Figure 13: Retinal Vein Occlusion Therapeutics Market, Global, Forecast ($m), 2011- 2019 24Figure 14: Retinal Vein Occlusion Therapeutics Market, The US, , Revenue ($m), 2006- 2011 25Figure 15: Retinal Vein Occlusion Therapeutics Market, The US, Forecast ($m), 2011- 2019 26Figure 16: Retinal Vein Occlusion Therapeutics Market, France, Revenue ($m), 2006- 2011 27Figure 17: Retinal Vein Occlusion Therapeutics Market, France, Forecast ($m), 2011- 2019 28Figure 18: Retinal Vein Occlusion Therapeutics Market, Germany, Revenue ($m), 2006- 2011 29Figure 19: Retinal Vein Occlusion Therapeutics Market, Germany,
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |